Takeda Pharmaceutical Ltd ADR (TAK) Stock Price, Quote & News

Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate,...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 81 3 3278-2111

Fax: 81 3 3278-2000

Website: www.takeda.com

Address:

1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, Japan

SparkyReturns Jun. 24 at 3:33 PM

$TAK Something to look at. Small cap investing idea: ICU recently beat down from a capital raise a few days ago, which was just reported will make them Nasdaq compliant. Waiting on confirmation. ICU has a unique SCD device which treats Acute Kidney Infection and has also been approved for compassionate and emergency use for Sepsis. FDA loves it so much has granted multiple breakthrough device designations, and has even awarded grants. Also Dept of Defense money to study use in burn or trauma cases. The device can calm the cytokine storm which can happen in a variety of conditions from AKI to sepsis to heart attacks to burn cases, Covid, etc. TAM in the tens of Billions. Current market cap approx. 8M. Read that again. Let that sink in. Reversal incoming. Cheers! $SYK $DVA $FMS

0 · Reply

biotech Jun. 24 at 12:34 PM

$SGMO +1.74 mL #gain of kidney function ... VS #losing kidney funktion with $TAK Replagal (agalsidase alfa), $SNY Fabrazyme (agalsidase beta) and $FOLD Galafold (migalastat) marketed treatment options range from -2.2 to -0.4 mL/min/1.73m2/year

0 · Reply

Quantumup Jun. 20 at 7:40 PM

Goldman Sachs, on 6/16,🏁 $ELVN Buy-$37. $TERN $AAPG $TAK INCY $NVS PFE BMY AZN #EHA2025 Goldman Sachs said in its initiation report: "Given continued positive Ph1 data and the announcement of a planned Ph3 initiation in 2026 for tyrosine kinase inhibitor (TKI) ELVN-001 in chronic myeloid leukemia (CML), we assign a Buy rating to $ELVN with a $37, 12-month price target, from the previous Early-Stage Biotech designation." Goldman Sachs went on to say:

0 · Reply

Quantumup Jun. 20 at 5:50 PM

TD Cowen Named Buy Rated $ELVN as a Best Smidcap Idea and said "Strong Data Position '001 To Advance Care In $B+ CML Market" $TERN $AAPG $TAK $NVS PFE AZN BMY #EHA2025 TD Cowen additionally said, "ELVN-001 is designed to improve upon prior TKIs for CML. At EHA ELVN-001 produced strong proof-of-concept data with a high MMR rate and benign safety profile, positioning it to become a standard therapy in this multi-$B market. ELVN-001 will enter pivotal development in 2026 and we project peak sales of $3B. We think $ELVN is undervalued for '001's potential. It is a top smidcap biotech pick."

0 · Reply

_ODENS_WRATH_ Jun. 18 at 9:17 PM

$TAK thats a 3x top which is creating a right shoulder to complete a Bearish H& S pattern 13.83 gets tested in my view

0 · Reply

Quantumup Jun. 17 at 7:52 PM

Stifel reitd $ALKS Buy-$42~"We remain Buy on $ALKS into the upcoming NT1 readout for ALKS2680, coming early-3Q. [ $TAK] Bottom line: the risk/reward on this specific catalyst isn't great, simply because investors mostly expect NT1 to be positive. However, our thesis here continues to center around a view that: (1) ALKS2680 is likely to succeed in NT1 and beyond--including in "normal" orexin populations like NT2/IH and (2) the Street's safety concerns with '2680--visual disturbances, etc.--are probably overdone. To this point, assuming the NT1 trial succeeds, safety/tolerability, and nuances around the ALKS2680 dose response, may end up being the most important points with implied readthrough onto prospects in NT2 (data this fall). The other question for NT1 is whether Takeda--with TAK-861--leaves any room for clinical differentiation. Admittedly while we think '2680 is a more potent drug with superior (QD) dosing, the bar is high; there is some, but not much, room on MWT, cataplexy and CGI-I."

0 · Reply

Quantumup Jun. 17 at 1:43 PM

Citi🏁 $PTGX Buy-$72. $TAK $JNJ Citi said in its note, "We are initiating coverage on Protagonist with a Buy/HR rating and a $72 target price, driven primarily by the potential of rusfertide (partnered with Takeda) in polycythemia Vera (PV) and oral IL-23 (icotrokinra - partnered with JNJ) in multiB$ inflammation indications. While we acknowledge share outperformance over 3 months (+40% vs +2% SPY), we believe rusfertide's impressive efficacy as demonstrated in phase 3 including improvement in QOL scores suggests the drug has strong potential in PV patients as despite therapeutic advancement there still remains unmet need. Rusfertide also has the potential to be added to therapies which could expand its use. However, we believe despite excellent efficacy and safety profile, cost-effectiveness still remains a concern, resulting in our in-line sales estimates (2032 combined WW revenues of $700M vs $680M VA cons)."

0 · Reply

Night_Owl_Biotech Jun. 16 at 2:29 PM

The attachment compares $ARDX & $PHAT valuations (market cap & EV) versus cumulative projected revenues per analysts & estimated gross margins using FY24 actuals through patent expiration. ARDX's Tenapanor has 2 brands, one of which is patented thru FY33 & the other thru FY34. PHAT's Voquezna is patented thru 5/2/32. Both appear to trade at roughly the same multiple of cumulative projected revenues thru FY34. ARDX trades at a slightly lower multiple of estimated gross margins (using actual FY24 as an estimate). PHAT pays $TAK a royalty which is the primary reason for the variance. PHAT's debt is a royalty obligation (that may dramatically skew comparisons). It's been our unqualified opinion ARDX offers a better risk v. reward profile after PHAT's recent run (but of course we could be wrong). We're curious to learn perspectives from PHAT investors. This is not investment advice. $XBI $NBI

1 · Reply

Love_To_Learn Jun. 13 at 10:28 AM

$TAK will need u for something important actually

0 · Reply

Quantumup Jun. 11 at 12:48 PM

H.C. Wainwright reiterated $UNCY Buy-$9 $TAK $SNY $ARDX $AKBA FMS H.C. Wainwright said in its note: "On June 10, Unicycive management announced that the FDA has identified a cGMP compliance-related deficiency with the company's third-party manufacturing vendor. The vendor in question is a subcontractor to Unicycives contract manufacturer (CDMO) and provides mostly fill/finish services for manufacturing OLC. Management reported that other than this issue, the FDA has not identified any other safety, efficacy, or manufacturing issues with the NDA submission. H.C. Wainwright went on to say:

1 · Reply

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

Jun 1, 2025, 8:00 AM EDT - 23 days ago

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

PTGX

May 27, 2025, 7:30 AM EDT - 4 weeks ago

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

May 14, 2025, 5:03 PM EDT - 5 weeks ago

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

May 11, 2025, 8:30 AM EDT - 6 weeks ago

Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise

May 9, 2025, 9:26 AM EDT - 6 weeks ago

Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call Transcript

May 8, 2025, 11:54 PM EDT - 6 weeks ago

Takeda Pharma less impacted by tariff, yen headwinds than other Japanese drugmakers: CEO

May 8, 2025, 10:32 AM EDT - 6 weeks ago

Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs

May 8, 2025, 2:36 AM EDT - 6 weeks ago

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

May 5, 2025, 8:00 AM EDT - 7 weeks ago

BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers

Apr 30, 2025, 8:05 AM EDT - 7 weeks ago

Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education

Apr 8, 2025, 7:15 AM EDT - 2 months ago

BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3

XOMA

Apr 1, 2025, 2:27 PM EDT - 3 months ago

Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns

Mar 13, 2025, 3:45 AM EDT - 3 months ago

Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds

Mar 3, 2025, 6:45 AM EST - 4 months ago

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

PTGX

Feb 24, 2025, 3:01 AM EST - 4 months ago

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

Jan 31, 2025, 8:30 AM EST - 5 months ago

Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued

Jan 30, 2025, 4:45 PM EST - 5 months ago

Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript

Jan 30, 2025, 9:00 AM EST - 5 months ago

Suffolk Celebrates Topping off for a Game-Changing New Takeda Facility in Kendall Square Where Science, Art and Community Will Converge

Jan 30, 2025, 2:04 AM EST - 5 months ago

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

Jan 30, 2025, 1:43 AM EST - 5 months ago

Japan's Takeda says Q3 profit slid 38%, trailing analyst estimates

Jan 30, 2025, 1:35 AM EST - 5 months ago

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

Jan 23, 2025, 7:14 PM EST - 5 months ago

Takeda-backed Ascentage Pharma aims to raise $126 mln in US IPO

Jan 21, 2025, 6:24 AM EST - 5 months ago

Takeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPO

Dec 27, 2024, 1:00 AM EST - 6 months ago

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Dec 12, 2024, 5:30 PM EST - 6 months ago

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Dec 7, 2024, 8:00 AM EST - 7 months ago

Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors

Dec 3, 2024, 12:37 PM EST - 7 months ago

Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst

KROS

Dec 3, 2024, 7:00 AM EST - 7 months ago

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

KROS

Nov 20, 2024, 11:30 AM EST - 7 months ago

Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform

Nov 15, 2024, 3:33 PM EST - 7 months ago

Hennessy Japan Fund's Masa Takeda on the top Japanese stocks investors should watch

Oct 31, 2024, 11:02 PM EDT - 8 months ago

Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript

Oct 31, 2024, 2:15 AM EDT - 8 months ago

Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments

Oct 31, 2024, 2:05 AM EDT - 8 months ago

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Oct 24, 2024, 8:00 AM EDT - 8 months ago

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem

Oct 7, 2024, 9:36 AM EDT - 9 months ago

Takeda Pharmaceuticals: An Interesting Option For Income Investors

Sep 26, 2024, 8:30 AM EDT - 9 months ago

Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development

TEM

Sep 24, 2024, 3:00 AM EDT - 9 months ago

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

Sep 19, 2024, 8:00 AM EDT - 9 months ago

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

Sep 18, 2024, 10:00 AM EDT - 9 months ago

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

Sep 4, 2024, 7:00 AM EDT - 10 months ago

US allows increased production of Takeda's ADHD drug to address shortage

Aug 12, 2024, 10:42 AM EDT - 11 months ago

Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues

Aug 7, 2024, 2:29 PM EDT - 11 months ago

Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?

Aug 7, 2024, 6:45 AM EDT - 11 months ago

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Aug 2, 2024, 3:21 PM EDT - 11 months ago

Takeda Pharmaceutical Company Limited (TAK) Q1 2025 Earnings Call Transcript

Aug 1, 2024, 8:00 AM EDT - 11 months ago

BostonGene Announces Partnership with Takeda to Evaluate Immunotherapies Using AI-Powered Molecular Profiling

Jul 31, 2024, 2:06 AM EDT - 11 months ago

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

Jul 19, 2024, 9:56 AM EDT - 1 year ago

Takeda's AI-Powered Strategy To Optimize Operations And Accelerate Its Pipeline

Jul 17, 2024, 8:15 AM EDT - 1 year ago

nference Establishes AI Initiative with Takeda to Advance Precision Medicine in Inflammatory Bowel Disease

Jun 26, 2024, 3:05 AM EDT - 1 year ago

Takeda Announces New Assignments of Directors

SparkyReturns Jun. 24 at 3:33 PM

0 · Reply

biotech Jun. 24 at 12:34 PM

0 · Reply

Quantumup Jun. 20 at 7:40 PM

0 · Reply

Quantumup Jun. 20 at 5:50 PM

0 · Reply

_ODENS_WRATH_ Jun. 18 at 9:17 PM

$TAK thats a 3x top which is creating a right shoulder to complete a Bearish H& S pattern 13.83 gets tested in my view

0 · Reply

Quantumup Jun. 17 at 7:52 PM

0 · Reply

Quantumup Jun. 17 at 1:43 PM

0 · Reply

Night_Owl_Biotech Jun. 16 at 2:29 PM

1 · Reply

Love_To_Learn Jun. 13 at 10:28 AM

$TAK will need u for something important actually

0 · Reply

Quantumup Jun. 11 at 12:48 PM

1 · Reply

jheerdink Jun. 4 at 6:22 PM

$SER Serina Therapeutics Strategically Adds Karuna Therapeutics’ CMO Dr. Stephen Brannan: A Power Move for CNS Innovation & Beyond ( $TAK $LLY ) https://vistapglobal.com/serina-therapeutics-strategically-adds-karuna-therapeutics-cmo-dr-stephen-brannan-a-power-move-for-cns-innovation-beyond-ser-bmy-tak-nvs-lly/ #

0 · Reply

Quantumup Jun. 4 at 1:21 PM

Lucid Capital🏁 $UNCY Buy-$12 and said "We are initiating coverage of Unicycive with a Buy rating and a $12/share 12-month Price Target" - "We estimate that OLC could capture >$1.3B in peak sales in the US within two years after launch in 2025" $TAK $SNY $ARDX AKBA $FMS Lucid Capital additionally said in its initiation report:

1 · Reply

Quantumup Jun. 3 at 4:30 PM

H.C. Wainwright reit'd $PTGX Buy-$80 and said, "At #ASCO2025, Protagonist and Takeda ( $TAK; not rated) presented full 32-week results from the Phase 3 VERIFY study of rusfertide in polycythemia vera (PV), further enhancing our confidence in rusfertide's blockbuster potential and its potential to become part of the standard of care (SOC) in PV. An independent PV specialist physician at the conference expressed her excitement about the VERIFY data and planned to put her patients in rusfertide after approval. It was stated plainly that rusfertide should become the standard of care in PV. The endorsement stands out, in our view, for lacking the qualifying statements that often accompany these presentations and discussions. Management noted rusfertide addressed the significant unmet need in the space that 78% of patients remain uncontrolled with HCT cycling above 45% in between treatments, which increases the risk of thrombotic events and cardiovascular events. H.C. Wainwright went on to say:

0 · Reply

prismmarketview Jun. 3 at 2:45 PM

$PTGX $TAK https://prismmarketview.com/protagonist-and-takeda-report-positive-phase-3-results-in-rare-blood-cancer-at-asco-2025/

0 · Reply

Quantumup Jun. 2 at 2:46 PM

JPMorgan reit $PTGX OW-$66, calls rusfertide's data 'practice changing' and said," $PTGX and partner $TAK presented rusfertide's pivotal Ph 3 Part 1a results in PV at #ASCO yesterday. Separately, $PTGX also hosted a call this morning to walk through the data." #ASCO25 $JNJ JPMorgan added, "We believe the data was a strong showcase of rus' profile, clearing the key questions remaining from 1Q's topline (note). While the tx arm appeared to have slightly higher proportion of sicker pts (6% delta in those requiring >=7 TP at BL), the clinical benefits were clearly unaffected. We believe the data finally put investors' safety worries fully to bed. Based on this data, we believe rus' is practicing change and will disrupt the current paradigm of how PV is treated. We continue to see rus' as the most under-appreciated component in $PTGX's SOTP, which we assume $18/share in our PT with $1.3bn risk-adjusted WW peak sales by 2034. Rus' with yesterday's data should warrant a second look from investors."

0 · Reply

DonCorleone77 Jun. 1 at 8:32 PM

$PTGX $TAK Protagonist, Takeda announces Phase 3 VERIFY study met primary endpoint Protagonist Therapeutics (PTGX) and Takeda (TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera, which met the primary and all key secondary endpoints. The data will be presented as a late-breaking oral presentation at the 61st American Society of Clinical Oncology, ASCO, Annual Meeting Plenary Session. The study met its primary endpoint, which was the proportion of patients achieving a clinical response, defined as the absence of phlebotomy eligibility during study Weeks 20-32. Study results demonstrated 76.9% of patients treated with rusfertide plus current standard of care achieved a clinical response, compared to 32.9% in the placebo plus current standard of care group. The response observed in the rusfertide arm was consistent across subgroups, regardless of risk status or type of concurrent cytoreductive therapy. In addition, all key secondary endpoints met statistical significance in favor of the rusfertide arm compared to the placebo arm in the VERIFY study.

0 · Reply

Broview May. 31 at 4:25 AM

$TAK added with confidence?

0 · Reply

TimRegan_WTR May. 29 at 5:50 PM

$ABBV $ALEC $DNLI $NVS $TAK

0 · Reply

research_WTR May. 29 at 5:42 PM

TREM2 Agonists: A New Frontier in Neurodegeneration Despite past clinical setbacks, Sanofi’s $470–$600M acquisition of Vigil Neuroscience signals renewed confidence in TREM2 as a key neuroinflammation target in Alzheimer’s and other disorders. 🔹 TREM2 helps microglia clear toxic proteins and regulate inflammation in the CNS 🔹 Past mAb candidates (ALEC/ABBV, DNLI) failed in trials due to lack of efficacy or safety concerns 🔹 Vigil’s oral TREM2 agonist (VG-3927) showed strong Phase 1 data and heads to Phase 2 in 2H25 🔹 Sanofi’s support may reshape the future of microglia-targeted neurotherapies Subscribe at our website to follow along with Robert Sassoon! $ALEC $ABBV $DNLI $TAK $NVS

0 · Reply

Quantumup May. 21 at 3:24 PM

Benchmark reiterated $UNCY Speculative Buy-$3. $TAK $SNY $ARDX $AKBA FMS Benchmark said in their note to investors: "Unicycive is currently awaiting FDA approval for its first product candidate, Oxylanthanum Carbonate, which is anticipated later this year. We are updating our model for the 1Q filings with no change to our forward expectations. In November, the company announced that the FDA accepted its NDA of Oxylanthanum Carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis, and set a PDUFA date of June 28, 2025. Benchmark additionally said:

1 · Reply

DonCorleone77 May. 19 at 8:16 PM

$VEEV $CRM $TAK Veeva has 'meaningful' Life Science head start over Salesforce, says Oppenheimer After Salesforce (CRM) announced a T20 commitment from Takeda (TAK) for Life Sciences Cloud for Customer Engagement, Oppenheimer says that extrapolating current commitments - namely Veeva's (VEEV) four to Salesforce's two - would imply about 67% share for Veeva, which is still within investor expectations of about 60%. Veeva already has a product in the market with over 50 customers live on Vault CRM and has also completed eight Vault CRM migrations, while Veeva expects to have its first T20 customer migrated by year-end, so it has "a meaningful head start," says the analyst, who has an Outperform rating and $280 price target on Veeva shares.

0 · Reply

pissed_of_retards May. 19 at 5:30 PM

$NVAX JJ, now it's your turn to announce new Combo partnership, either $MRK or $NVO or $TAK or $JNJ. Price per Combo $2.5 - $3B

0 · Reply

Market Cap	46.84B
Revenue (ttm)	30.24B
Net Income (ttm)	712.32M
EPS (ttm)	N/A
PE Ratio	9.35
Forward PE	8.64
Profit Margin	2.36%
Debt to Equity Ratio	0.65

Volume	2,277,200
Avg Vol	2,074,552
Day's Range	N/A - N/A
Shares Out	3.18B
Stochastic %K	60%
Beta	0.23
Analysts	Strong Sell
Price Target	$16.67